Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 01-Dec-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Diclofenac Sodium Topical Solution USP, 2% w/w.
Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 01-Dec-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Diclofenac Sodium Topical Solution USP, 2% w/w.